← Back to Clinical Trials
Recruiting NCT07568626

NCT07568626 Factors for Prolonged Hospital Stays in Patients Undergoing ERCP

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07568626
Status Recruiting
Phase
Sponsor Air Force Military Medical University, China
Condition Post-ERCP Adverse Events
Study Type OBSERVATIONAL
Enrollment 504 participants
Start Date 2026-02-15
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 504 participants in total. It began in 2026-02-15 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Endoscopic retrograde cholangiopancreatography (ERCP) is a crucial minimally invasive technique for the diagnosis and treatment of biliary and pancreatic diseases. However, it remains technically demanding and carries a postoperative adverse event (AE) rate exceeding 10% (e.g., pancreatitis, bleeding, and perforation), which subsequently leads to prolonged length of stay (LOS) and increased healthcare costs. With the rapid acceleration of population aging, the clinical demand for ERCP among the elderly has surged. Although ERCP is generally considered safe for older adults, advanced age also increases the risk of ERCP-related AEs and prolonged LOS. While previous studies investigated the outcomes of ERCP in elderly patients, those studies were predominantly retrospective, accompanied by selection bias. Moreover, insufficient factors were included in those retrospective studies. Importantly, some aging-related parameters, such as frailty, functional reserve, cognitive and psychological status, were not included in previous studies. Therefore, the investigators conducted a prospective, multicenter cohort study aimed at investigating outcomes in elderly patients undergoing ERCP and comprehensive factors (patient-related, procedure-related, and geriatric factors) associated with adverse outcomes.

Eligibility Criteria

Inclusion Criteria: 1. Patient age ≥ 65 years 2. Scheduled to undergo ERCP procedure Exclusion Criteria: 1. Severe cognitive dysfunction 2. Severe hearing impairment 3. Known or suspected gastrointestinal perforation 4. Hemodynamic instability 5. Pregnant or lactating women 6. Unable to sign the informed consent form

Contact & Investigator

Central Contact

Yanglin Pan, M.D

✉ yanglinpan@hotmail.com

📞 13991811225

Frequently Asked Questions

Who can join the NCT07568626 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Post-ERCP Adverse Events. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07568626 currently recruiting?

Yes, NCT07568626 is actively recruiting participants. Contact the research team at yanglinpan@hotmail.com for enrollment information.

Where is the NCT07568626 trial being conducted?

This trial is being conducted at Xiamen, China, Xi'an, China, Xi'an, China, Xi'an, China and 1 additional location.

Who is sponsoring the NCT07568626 clinical trial?

NCT07568626 is sponsored by Air Force Military Medical University, China. The trial plans to enroll 504 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology